Executive Director, HEOR, Europe

1 day ago Be among the first 25 applicants>

Revolution Medicines is a clinical‑stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity

The Executive Director, HEOR Europe will lead the strategy, execution, and provide scientific leadership across health economics, outcomes research, and real‑world evidence (RWE) to optimize the value demonstration of Revolution Medicines oncology portfolio across European markets. They will develop and lead a team of HEOR professionals across t...